Kahraman, Deniz, Scheffler, Matthias ORCID: 0000-0002-9031-1368, Zander, Thomas, Nogova, Lucia, Lammertsma, Adriaan A., Boellaard, Ronald ORCID: 0000-0002-0313-5686, Neumaier, Bernd ORCID: 0000-0001-5425-3116, Ullrich, Roland T., Holstein, Arne, Dietlein, Markus, Wolf, Juergen and Kobe, Carsten (2011). Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non-Small Cell Lung Cancer Using F-18-FDG and 3 '-Deoxy-3 '-F-18-Fluorothymidine PET. J. Nucl. Med., 52 (12). S. 1871 - 1878. RESTON: SOC NUCLEAR MEDICINE INC. ISSN 1535-5667

Full text not available from this repository.

Abstract

The purpose of this study was to evaluate the relevance for the prediction of clinical benefit of first-line treatment with erlotinib using different quantitative parameters for PET with both F-18-FDG and 3'-deoxy-3'-F-18-fluorothymidine (F-18-FLT) in patients with advanced non-small cell lung cancer. Methods: Data were used from a prospective trial involving patients with untreated stage IV non-small cell lung cancer. F-18-FDG PET and F-18-FLT PET were performed before and 1 (early) and 6 (late) weeks after erlotinib treatment. Several quantitative standardized uptake values (SUVs) using different definitions of volumes of interest with varying isocontours (maximum SUV [SUVmax], 2-dimensional peak SUV [SUV2Dpeak], 3-dimensional [3D] peak SUV [SUV3Dpeak], 3D isocontour at 50% of the maximum pixel value [SUV50], 3D isocontour at 50% adapted for background [SUVA50], 3D isocontour at 41% of the maximum pixel value adapted for background [SUVA41], 3D isocontour at 70% of the maximum pixel value [SUV70], 3D isocontour at 70% adapted for background [SUVA70], and relative SUV threshold level [SUVRTL]) and metabolically active volume measurements were obtained in the hottest single tumor lesion and in the sum of up to 5 lesions per scan in 30 patients. Metabolic response was defined as a minimum reduction of 30% in each of the different SUVs and as a minimum reduction of 45% in metabolically active volume. Progression-free survival (PFS) was compared between patients with and without metabolic response measured with each of the different parameters, using Kaplan-Meier statistics and a log-rank test. Results: Patients with a metabolic response on early F-18-FDG PET and F-18-FLT PET in the hottest single tumor lesion as well as in the sum of up to 5 lesions per scan had a significantly longer PFS, regardless of the method used to calculate SUV. However, the highest significance was obtained for SUVmax, SUV50, SUVA50, and SUVA41. Patients with a metabolic response measured by SUVmax and SUV3Dpeak on late F-18-FDG PET in the hottest single tumor lesion had a significantly longer PFS. Furthermore, Kaplan-Meier analyses showed a strong association between PFS and response seen by metabolically active volume, measured either in early F-18-FLT or in late F-18-FDG. Conclusion: Early F-18-FDG PET and F-18-FLT PET can predict PFS regardless of the method used for SUV calculation. However, SUVmax, SUV50, SUVA50, and SUVA41 measured with F-18-FDG might be the best robust SUV to use for early response prediction. Metabolically active volume measurement in early F-18-FLT PET and late F-18-FDG PET may have an additional predictive value in monitoring response in patients with advanced non-small cell lung cancer treated with erlotinib.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Kahraman, DenizUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scheffler, MatthiasUNSPECIFIEDorcid.org/0000-0002-9031-1368UNSPECIFIED
Zander, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nogova, LuciaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lammertsma, Adriaan A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Boellaard, RonaldUNSPECIFIEDorcid.org/0000-0002-0313-5686UNSPECIFIED
Neumaier, BerndUNSPECIFIEDorcid.org/0000-0001-5425-3116UNSPECIFIED
Ullrich, Roland T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Holstein, ArneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dietlein, MarkusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wolf, JuergenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kobe, CarstenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-484050
DOI: 10.2967/jnumed.111.094458
Journal or Publication Title: J. Nucl. Med.
Volume: 52
Number: 12
Page Range: S. 1871 - 1878
Date: 2011
Publisher: SOC NUCLEAR MEDICINE INC
Place of Publication: RESTON
ISSN: 1535-5667
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
POSITRON-EMISSION-TOMOGRAPHY; EARLY PREDICTION; ROI DEFINITION; BREAST-CANCER; TUMOR; QUANTIFICATION; PROLIFERATION; GEFITINIBMultiple languages
Radiology, Nuclear Medicine & Medical ImagingMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/48405

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item